Relationship between diabetic polyneuropathy, serum visfatin, and oxidative stress biomarkers.

Banu Buyukaydin, Eray Metin Guler, Tahsin Karaaslan, Atilla Olgac, Mehmet Zorlu, Muharrem Kiskac, Abdurrahim Kocyigit
Author Information
  1. Banu Buyukaydin: Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey. bbuyukaydin@hotmail.com.
  2. Eray Metin Guler: Department of Medical Biochemistry, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey.
  3. Tahsin Karaaslan: Department of Nephrology, Istanbul Medeniyet University Medical Faculty, İstanbul 34093, Turkey.
  4. Atilla Olgac: Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey.
  5. Mehmet Zorlu: Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey.
  6. Muharrem Kiskac: Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey.
  7. Abdurrahim Kocyigit: Department of Medical Biochemistry, Bezmialem Vakif University Medical Faculty, İstanbul 34093, Turkey.

Abstract

BACKGROUND: Diabetic polyneuropathy is a very common complication of diabetes. Numerous studies are available in terms of pathogenesis. But examination methods with low reliability are still not standardized and generally time consuming. High-sensitive, easy-to-access methods are expected. Biochemical markers are one of the subjects of research. We aimed to discover a potential biomarker that can be used for this purpose in patients with diabetes who have not yet developed symptoms of neuropathy.
AIM: To determine the place and availability of visfatin and thiol-disulfide homeostasis in this disorder.
METHODS: A total of 392 patients with type 2 diabetes mellitus were included in the study. The polyneuropathy clinical signs were evaluated with the Subjective Peripheral Neuropathy Screen Questionnaire and Michigan Neuropathy Screening Instrument questionnaire and examination. The biochemical parameters, oxidative stress markers, visfatin, and thiol-disulfide homeostasis were analyzed and correlated with each other and clinical signs.
RESULTS: Subjective Peripheral Neuropathy Screen Questionnaire and Michigan Neuropathy Screening Instrument questionnaire with examination scores were correlated with each other and diabetes duration ( < 0.005). Neuropathy related symptoms were present in 20.7% of the patients, but neuropathy related findings were observed in 43.9% of the patients. Serum glucose, glycated hemoglobin, and visfatin were positively correlated with each other. Also, these parameters were positively correlated with the total oxidative stress index. Total and native thiol was positively correlated with total antioxidant status and negatively with oxidant status. Inversely thiol-disulfide positively correlated with higher glucose and oxidant status and negatively with total antioxidant status ( < 0.005). There was no correlation between visfatin and thiol-disulphide ( = 0.092, = 0.086). However, a significant negative correlation was observed between visfatin and total with native thiol ( < 0.005, = -0.338), ( < 0.005, = -0.448).
CONCLUSION: Diagnosis of neuropathy is one of the issues studied in patients with diabetes. Visfatin and thiol-disulfide balance were analyzed for the first time in this study with inspiring results.

Keywords

References

  1. Peptides. 2013 Jan;39:55-8 [PMID: 23174347]
  2. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Mar;161(1):31-40 [PMID: 28228651]
  3. Neurol Res. 2018 Mar;40(3):166-172 [PMID: 29359643]
  4. Jpn J Infect Dis. 2017 May 24;70(3):258-262 [PMID: 27795469]
  5. Diabetes Res Clin Pract. 2015 Nov;110(2):166-71 [PMID: 26421363]
  6. Nutr Metab Cardiovasc Dis. 2007 Dec;17(10):734-40 [PMID: 17321120]
  7. J Diabetes Complications. 2015 Mar;29(2):212-7 [PMID: 25498300]
  8. Iran J Kidney Dis. 2018 May;12(3):163-168 [PMID: 29891746]
  9. Diabetes Care. 2013 Oct;36(10):3187-94 [PMID: 23723354]
  10. Mol Biol Rep. 2012 Sep;39(9):8669-78 [PMID: 22718504]
  11. Pol Arch Intern Med. 2018 Aug 31;128(7-8):434-439 [PMID: 30057390]
  12. J Clin Endocrinol Metab. 2009 Jun;94(6):2157-63 [PMID: 19276232]
  13. Lancet Diabetes Endocrinol. 2016 Sep;4(9):723-725 [PMID: 27180137]
  14. J Trauma Acute Care Surg. 2017 Sep;83(3):507-519 [PMID: 28697011]
  15. J Fam Pract. 2006 Jun;55(6):505-8 [PMID: 16750065]
  16. Arch Neurol. 1998 Dec;55(12):1513-20 [PMID: 9865794]
  17. Am J Gastroenterol. 2011 May;106(5):957-67 [PMID: 21245835]
  18. Clin Biochem. 2004 Feb;37(2):112-9 [PMID: 14725941]
  19. J Public Health Res. 2015 Jul 30;4(2):450 [PMID: 26425491]
  20. Lancet Neurol. 2012 Jun;11(6):521-34 [PMID: 22608666]
  21. J Matern Fetal Neonatal Med. 2016 Nov;29(22):3699-704 [PMID: 26769102]
  22. Diabetes Care. 2013 Nov;36(11):3663-70 [PMID: 24009302]
  23. Neurosci Lett. 2011 Oct 24;504(2):121-126 [PMID: 21945543]
  24. N Engl J Med. 2007 Jan 18;356(3):213-5 [PMID: 17229948]
  25. AIDS Read. 2005 Jul;15(7):341-4, 348-9, 354 [PMID: 16044575]
  26. Korean J Intern Med. 2018 Mar;33(2):367-382 [PMID: 27809453]
  27. Diabetes Metab Res Rev. 2011 Oct;27(7):629-38 [PMID: 21695762]
  28. Neurol Sci. 2012 Aug;33(4):875-80 [PMID: 22120188]
  29. Diabet Med. 2012 Jul;29(7):937-44 [PMID: 22417277]
  30. Diabetes Technol Ther. 2015 Feb;17(2):134-41 [PMID: 25478993]
  31. Clin Biochem. 2005 Dec;38(12):1103-11 [PMID: 16214125]
  32. Oxid Med Cell Longev. 2016;2016:4569108 [PMID: 27525051]
  33. Cardiovasc Res. 2017 Jul 1;113(9):1009-1023 [PMID: 28838042]
  34. Diabetes Care. 2001 Feb;24(2):250-6 [PMID: 11213874]
  35. Diabetes Care. 1994 Nov;17(11):1281-9 [PMID: 7821168]
  36. Ann Agric Environ Med. 2012;19(4):742-5 [PMID: 23311800]
  37. Clin Biochem. 2014 Dec;47(18):326-32 [PMID: 25304913]
  38. J Diabetes Metab Disord. 2016 Mar 25;15:8 [PMID: 27019831]
  39. Diabetol Metab Syndr. 2018 May 15;10:41 [PMID: 29785210]
  40. Diabetol Metab Syndr. 2018 Feb 21;10:8 [PMID: 29483946]
  41. J Int Med Res. 2018 May;46(5):1779-1790 [PMID: 29517942]
  42. Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):136-142 [PMID: 29298534]
  43. Exp Clin Endocrinol Diabetes. 2020 Feb;128(2):77-81 [PMID: 29378378]
  44. Neuron. 2017 Mar 22;93(6):1296-1313 [PMID: 28334605]

Word Cloud

Created with Highcharts 10.0.0visfatincorrelated0diabetespatientstotalNeuropathyneuropathythiol-disulfidestress<005positivelystatus=DiabeticpolyneuropathyexaminationoxidativemethodstimemarkersonesymptomshomeostasisstudyclinicalsignsSubjectivePeripheralScreenQuestionnaireMichiganScreeningInstrumentquestionnaireparametersanalyzedrelatedobservedglucosenativethiolantioxidantnegativelyoxidantcorrelation-0VisfatinBACKGROUND:commoncomplicationNumerousstudiesavailabletermspathogenesislowreliabilitystillstandardizedgenerallyconsumingHigh-sensitiveeasy-to-accessexpectedBiochemicalsubjectsresearchaimeddiscoverpotentialbiomarkercanusedpurposeyetdevelopedAIM:determineplaceavailabilitydisorderMETHODS:392type2mellitusincludedevaluatedbiochemicalRESULTS:scoresdurationpresent207%findings439%SerumglycatedhemoglobinAlsoindexTotalInverselyhigherthiol-disulphide092086Howeversignificantnegative338448CONCLUSION:DiagnosisissuesstudiedbalancefirstinspiringresultsRelationshipdiabeticserumbiomarkersfootEarlydetectionOxidativeThiol-disulfideprotein

Similar Articles

Cited By